Since the original observations of Huggins and Hodges that prostate cancers are androgen dependent, androgen ablation therapy has been the gold standard for the treatment of advanced prostate cancer (CaP). Androgen receptor (AR) is believed to play critical roles in the development and progression of CaP. Treatment for neoadjuvant, adjuvant and recurrent disease all center on the regulation and manipulation of the androgen pathway, in which AR plays an integral role. Recent discoveries that frequent overexpression of ETS-related proto-oncogenes may be driven by AR as a consequence of common genomic rearrangements can hold the key towards the understanding of early phases of prostate cancer. Furthermore, AR function evolves as the cell changes towards a clinically androgen depletion independent state. Comprehension of AR function, regulation and abnormalities are increasingly refined towards the understanding of the role of AR in CaP, and in therapeutic applications. Development of future therapy for CaP will be aided by improving the knowledge of dysfunctions of AR and its network in prostate cancer. This review focuses salient features of AR and on the recent advances addressing AR dysfunctions in prostate cancer.
Balanced differentiation and cell growth-promoting functions of androgen receptor (AR) are evident during the normal development and maintenance of male organs. These properties are largely attributed to the transcription factor functions of AR mediating the physiologic effects of androgens by binding to specific DNA sequences known as androgen-responsive elements (AREs) modulating the transcription of androgen-responsive genes. 1 Therefore, a great deal of effort has been made to define the spectrum of AR target genes by both experimental and bioinformatic tools. 2, 3 AR belongs to a superfamily of nuclear hormone receptors. These receptors are ligand-inducible regulators of gene expression. Ligand binding alters the protein confirmation, allowing binding of coactivator molecules to modulate androgenic hormone signals and to mediate transcriptional initiation. 4 AR has four functional domains. A conserved DNA-binding domain, a hinge region, a COOH-terminal ligand-binding domain and an NH2-terminal domain. 5 The NH2-terminal domain is the most variable and least conserved. The AR gene is located on the long arm of the X-chromosome. The implication of location on the X-chromosome is that the lack of a corresponding wild-type allele in male allows phenotypic prevalence when mutation occurs. AR is nearly ubiquitous in mammalian tissues sequestered and stabilized in the cytoplasm bound to heat shock proteins. 6 Upon binding testosterone or dihydrotestosterone, it undergoes a series of conformational changes that lead to translocation to the nucleus, allowing interactions with androgen response elements at various androgen target genes. 7, 8 Besides transcription factor functions, AR is important in integrating cellular signals by interacting with central signal-transduction pathways. 9 Non-nuclear functions of AR are likely coordinated with its nuclear activity that occurs following translocation to the nucleus. 4, 9 
AR coregulators
Coregulators are macromolecules that modulate the transcriptional activity of AR by influencing a number of functional properties, including ligand specificity as well as DNA-binding capacity. There are multiple coregulators and a complete discussion of all is beyond the scope of this review, rather we refer here to excellent reviews in the literature. 10, 11 Both coactivators and corepressors exist, and mutations or alterations can result in aberrant functions of AR that may contribute to prostate cancer (CaP). Coactivators may represent a mechanism by which CaP cells become androgen independent. In an androgen-dependent state, coactivators enhance target gene transcription, whereas increased sensitivity to AR coactivators may be responsible for androgen-independent prostate cancer. 12 Studies of coregulators have revealed differences in expression in CaP; TIF2 and SRC1 were found to be overexpressed in recurrent CaP; further, TIF2 increases the responsiveness of AR to adrenal androgens. 13 Gelsolin increases in CaP after androgen ablation and promotes transactivation in the presence of androgen.
14 ARA55 is reported to enhance AR transcriptional activity in response not only to normally weak adrenal androgens, but also to the antiandrogens hydroxyflutamide and other nonandrogenic steroids. 15 Surgical or medical castration may reduce androgen concentration, but subsequent increases in AR coactivators may rescue cancerous cells, allowing them to progress to clinically androgen depletion independent form. Alternatively, acquired mutations in AR may promote hypersensitivity to coactivators. 16 In addition to coregulators, specific transcription factors play a role in transcription regulation. FOXO3a induces AR-promoter activity, enhancing gene expression, though potential linkage to CaP remains unknown; however, a recent report indicates that it may be signaled by the antiapoptotic factor Akt. 17 
AR and chromatin
Specific histone modifications provide permissive conditions for the binding of AR to cognate sequences, facilitating the transcriptional activation of androgenregulated genes. However, repression of AR nuclear functions can be directly controlled by cell cycle regulation linked to histone modification mechanisms. 18 The Coactivator Associated Arginine Methyl Transferase (CARM1) was shown to mediate histone H3 methylation at androgen-regulated enhancer elements in response to androgenic stimuli. 19 Histone methylation of AR target sequences can play significant roles in the dynamics of AR binding to cognate sequences. Interestingly, it was shown that bicalutamide, an AR antagonist, can facilitate histone methylation. 20, 21 Therefore, standard antiandrogen treatment may also work as a chromatin structure modifier. Moreover, in hormone ablation independent prostate cancer cells, chromatin remodeling is conductive to the ligand independent activity of AR. 22 
Androgen-regulated genes
Upon binding to androgen hormone, AR translocates to the nucleus and acts as a transcription factor. In the nucleus, ligand-bound AR binds to specific DNA sequences, AREs controlling the transcription of androgen-regulated genes (ARGs). ARGs have been thoroughly investigated in large-scale gene expression studies. 1 To define androgen-inducible genes in CaP, cells were treated with various doses of androgen and gene expression kinetic and dose-dependent changes were monitored. 2, 23 Identification of ARGs lead to the thorough examination of promoter and enhancer sequences of ARGs. 24 Further studies revealed that functional AREs consist of composite DNA recognition sites, suggesting that other transcription factors may actively modulate the transcription factor function of AR. 3 The utility of ARGs as potential biomarkers in androgen-independent disease is intriguing. Although prostate-specific antigen (PSA) is an excellent marker for recurrence, it is not precise in defining cancer-specific alteration in AR signaling. 25 Importantly, a panel of ARGs could serve as a tool to define therapeutic targets in CaP progression.
ETS-related oncogenes transformed into ARGs in CaP
Recent findings highlighted the overexpression of the ETS-related proto-oncogene, ERG in the majority of primary prostate tumors. 26 In an effort to explain this overexpression, it was shown that the elevated expression of the Ets family members (predominantly ERG) in tumor cells is due to genetic rearrangements, resulting in a fusion of the androgen-inducible TMPRSS2 gene promoter to the ERG or ETV1 loci that may result in the activation of proto-oncogenes by androgens. [27] [28] [29] However, an inverse correlation was observed between PSA-free survival and ERG expression. 26 Elucidation of this paradox may hold an important key towards the understanding of CaP progression. 30, 31 Although the mechanism of ERG downstream functions is not well understood, the exceptionally high frequency of TMPRSS2-ERG gene fusion may be tightly linked to causative changes at early stages of CaP progression. Early detection of elevated ERG gene expression and the detection of TMPRSS2-ETS-related proto-oncogene fusion transcripts may lead to the development of diagnostic tools of unprecedented accuracy.
AR and signal transduction
Best understood among the post-translational modifications of AR, phosphorylation plays a critical role in signal transduction by protein kinases that may be involved in the dynamic regulation of various receptor functions, such as ligand binding, nuclear translocation, receptor dimerization, DNA binding and protein-protein interactions. 9 Phosphorylation typically occurs at the Nterminal transactivation, C-terminal ligand-binding and the DNA-binding domains. Protein kinases implicated in AR phosphorylation are activated by a variety of signals: mitogen-activated protein kinases (MAPKs)-, Akt-, protein kinase A (PKA)-, protein kinase C (PKC)-mediated pathways. 9 Furthermore, protein kinases may facilitate the recruitment of coactivators or other components of the transcription machinery cooperating with AR to enhance transcription activation. 32 Phosphorylation can sensitize AR to low levels of androgens or alternative steroids. Aberrant AR phosphorylation has been demonstrated in hormone refractory CaP when MAPK and Akt are upregulated, resulting in hypersensitization of AR. 33 Akt activation is inhibited by the tumor suppressor gene PTEN, suggesting that loss of PTEN, a frequent abnormAndrogen receptor and prostate cancer E Richter et al ality detected in advanced prostate cancer, may lead to progression to androgen independence in CaP. [34] [35] [36] [37] 
AR and growth factors
Growth factors and cytokines also play an important role in the regulation of AR. Interleukin-6 (IL-6) is a proinflammatory cytokine that is elevated in sera and tissue of patients with prostate cancer. IL-6 is able to activate AR in a ligand-independent manner. 38 Cyclin D1 acts as a corepressor and directly inhibits the activity of IL-6. 39 Also, insulin-like growth factor has been shown to be elevated in CaP, activating AR in a ligand-independent manner. 40 Similarly, epidermal growth factor was shown to activate AR in a ligand-independent manner. 41 
Proteasomal degradation of androgen receptor
Degradation of AR plays an integral role in the regulation of AR function. AR does not undergo ligand-dependent downregulation at the protein level, and is instead regulated by systemic protein degradation pathways, specifically the MDM2-ubiquitin-proteosome pathway. 8 The NEDD4 ubiquitin ligase recruiting protein PMEPA1 may also play important roles in this pathway. 42 Therapeutic approaches facilitating AR degradation by the ubiquitin-proteasome pathway may open new avenues in CaP medicine. 43 Although, not fully understood, blockade of the proteasome pathway by hyperthermia or specific blockers may also have future therapeutic values. 44 Reducing AR protein levels in CaP may become a powerful strategy in CaP treatment. 45 
AR and CaP
It is well known that CaP is driven by androgen. Indeed, cancer and hypertrophy will not occur in the absence of androgen. 46 Men castrated before puberty or those with 5a-reductase deficiency do not develop CaP. 47 Paradoxically low pretreatment testosterone predicts a higher likelihood of non-organ confined disease in radical prostatectomy patients, as well as outcome for patients with bone metastatic disease. 48, 49 Interestingly, high levels of AR is associated with aggressive clinicopathologic features and with decreased biochemical recurrence-free survival in CaP patients treated with radical prostatectomy. 50 These observations are consistent with reports demonstrating that increases in AR mRNA and protein levels are both necessary and sufficient to convert CaP growth from hormone-sensitive to a hormonerefractory stage, and is dependent on a functional AR ligand-binding domain. 51 It may be that activity of AR and levels of AR, rather than testosterone, is the driving force for CaP. It was shown that low levels of testosterone was associated with higher androgen receptor density in CaP, as well as higher Gleason score. 50 In AfricanAmerican men who are at higher risk for CaP and have higher mortality, tumor volume and more advanced stage have 81% higher levels or AR compared with Caucasian men. 52 
AR and androgen depletionindependent CaP
Whereas CaP is initially sensitive to hormone ablation, ultimately it progresses to a clinically androgen-independent phase. The transition to an androgen ablation insensitive state following the onset of androgen deprivation therapy is typically less than 2 years. Determination of the cause for transformation to an androgen depletion-independent state will require further studies. However, increases in cell growth-promoting functions and the apparent loss of differentiation properties of AR may play important roles ( Figure 1 ). As outlined above, AR integrates signals from multiple regulatory pathways and disruptions in any may lead to the loss of AR functional integrity. Also, mutations of AR may play a role in this process. AR mutations that have the greatest effect in androgen-insensitive CaP are those that alter ligand interaction or those that increase transcriptional activity. 53 Often they make the AR more promiscuous for steroid ligands such that they bind estrogen, aldosterone, cortisone, androgen and the antiandrogen hydroxyflutamide. 54 Significantly, AR mutation can directly promote CaP cell growth and suppress the protective role of p53 pointing to tight regulatory loop between AR and p53. 55, 56 Ultimately all recurrent disease progresses to a phase in which it is androgen depletion independent. An interesting phenomenon occurs in which antiandrogens begin to act as agonists. In fact, the withdrawal of the anti-androgen will often result in a decrease in PSA. While exact mechanisms are not fully understood, postulated mechanisms can be divided into three groups. The first is DNA-based alterations in the AR gene, such as amplification or point mutations that occur in the minority of patients. The second involves active androgen receptor signaling in which increased MAPK signaling mediated by oncogenes such as ERB2 or HRAS cause ligand-independent activation of AR. Recent observations suggest that AR mutation (T877A) commonly associating with a subset of metastatic CaP can antagonize apoptotic effects of wild-type p53. Thus, AR mutations may interfere with normal cell death pathways. 55 The third is that growth and survival-promoting functions of the androgen receptor are bypassed, such that AR is no longer relevant to disease progression. 51 Gain of function by AR mutation was demonstrated in vitro by induction of LNCaP cells with bicalutamide. Although bicalutamide initially suppressed growth, it ultimately became an agonist owing to a mutation 
